| 000 | 02674nam a22003617a 4500 | ||
|---|---|---|---|
| 008 | 220926s20222022 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a2072-6694 | ||
| 024 | _a10.3390/cancers14112596 [doi] | ||
| 024 | _acancers14112596 [pii] | ||
| 024 | _aPMC9179451 [pmc] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a35681574 | ||
| 245 | _aBERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. | ||
| 251 | _aCancers. 14(11), 2022 May 24. | ||
| 252 | _aCancers (Basel). 14(11), 2022 May 24. | ||
| 253 | _aCancers | ||
| 260 | _c2022 | ||
| 260 | _fFY2022 | ||
| 260 | _p2022 May 24 | ||
| 265 | _sepublish | ||
| 265 | _tPubMed-not-MEDLINE | ||
| 266 | _d2022-07-06 | ||
| 520 | _aBERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant-adjuvant pertuzumab-trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w x 4 paclitaxel qw x 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w x 4 docetaxel q3w x 4 (B) as per physician's choice. Pertuzumab-trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of >=10% points from baseline to <50% in Cohort A, as did 20 (10.5%) in B during the adjuvant period (12 (6.2%) in A and 7 (3.6%) in B during TFFU). The five-year event-free survival rates in Cohorts A and B were 90.8% (95% CI: 86.5, 95.2) and 89.2% (84.8, 93.6), respectively. The five-year overall survival rates were 96.1% (95% CI: 93.3, 98.9) and 93.8% (90.3, 97.2), respectively. The final analysis of BERENICE further supports pertuzumab-trastuzumab-based therapies as standard of care for high-risk, HER2-positive EBC. | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 656 | _aAssociate Dean for Research Development | ||
| 656 | _aMedStar Health | ||
| 657 | _aJournal Article | ||
| 700 | _aSwain, Sandra M | ||
| 790 | _aColomer R, Dadswell K, Dang C, de Haas SL, de la Cruz-Merino L, Delaloge S, Eiger D, Ewer MS, Ferrero JM, Restuccia E, Sarkar S, Swain SM, Verrill M, Werner TL | ||
| 856 |
_uhttps://dx.doi.org/10.3390/cancers14112596 _zhttps://dx.doi.org/10.3390/cancers14112596 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c418 _d418 |
||